Oncology Drug Candidate COTI-2 Wins U.S. Patent

Canada's Critical Outcome Technologies said a composition of matter patent has been granted for the company's oncology drug candidate.

Canadian biotechnology company Critical Outcome Technologies Inc. (COTI)  announced yesterday that a composition of matter patent has been granted for the company's oncology drug candidate, COTI-2, by the United States Patent and Trademark Office (USPTO).

This patent provides protection for COTI-2 until 2030.

COTI-2’s specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers that over express Akt/Akt2. Over expression of Akt/Akt2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors producing excess active Akt/Akt2 ranges from 20% to 100% depending on the cancer type.